Search Results

Enrollment Completed for ACIST-FFR Multicenter Study

January 11, 2017—Acist Medical Systems, Inc. announced that enrollment is complete for its Assessment of Catheter-Based Interrogation and Standard Techniques for Fractional Flow Reserve (ACIST-FFR) study of FFR measurement using the company's Navvus catheter.  Beginning in November 2015, the ACIST-FFR study enrolled 240 patients at 12 sites across the United States.

CathWorks FFRangio System’s ALL-RISE Trial Completes Enrollment

January 6, 2025—CathWorks recently announced the completion of enrollment for the ALL-RISE randomized controlled trial, evaluating the clinical and economic benefits of the CathWorks FFRangio system in diagnosing and treating coronary artery disease.

Acist Medical Begins Enrollment in FFR Study

November 16, 2015—Acist Medical Systems, Inc. announced the beginning of enrollment in the company-sponsored FFR Study, an assessment of catheter-based interrogation and standard techniques for fractional flow reserve (FFR) measurement.

First Patient Enrolled in CathWorks ALL-RISE Study Evaluating FFRangio System

June 28, 2023—CathWorks announced that the first patient has been enrolled in the ALL-RISE study sponsored by the company.

FAME II Data Show Cost Effectiveness and Improved Outcomes With FFR-Guided PCI

October 24, 2012—St.

St. Jude Medical Begins FAME II Enrollment

May 25, 2010—St.

Two-Year FAME Results Show Benefit of FFR Guidance

September 24, 2009—TCT Daily, the conference newspaper for the Transcatheter Cardiovascular Therapeutics (TCT) 2009 scientific symposium in San Francisco, reported that 2-year results from the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) trial presented at this year's meeting confirm and extend the 1-year results reported at TCT 2008.

St. Jude Medical Commences Enrollment in FAME II Trial

May 25, 2010—At the EuroPCR 2010 conference in Paris, St.

Medtronic Completes Acquisition of CathWorks

April 20, 2026—Medtronic announced it has completed its acquisition of CathWorks, a privately held medical device company focused on the diagnosis and treatment of coronary artery disease with its fractional flow reserve (FFR) diagnostic technology.

ALL-RISE Compares CathWorks’ FFRangio to Invasive Pressure Wire Guidance

April 3, 2026—CathWorks announced 1-year clinical outcomes of the ALL-RISE trial.

FAME 3 Trial Compares FFR-Guided PCI Versus CABG in Three-Vessel CAD

November 4, 2021—The primary results of FAME 3, the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation 3 trial, found that percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) did not meet noninferiority for 1-year adverse events compared to coronary artery bypass grafting (CABG) in patients with three-vessel coronary artery disease (3V-CAD).

CathWorks Announces Completion of Enrollment in FAST-FFR Trial

August 16, 2018—CathWorks Limited announced that its FAST-FFR trial is fully enrolled ahead of schedule.